Department of Renal Medicine, King's College London, London, UK.
Chin Med. 2010 Dec 14;5:42. doi: 10.1186/1749-8546-5-42.
Traditional Chinese medicine (TCM) is widely used in the European Union (EU) and attracts intense research interests from European scientists. As an emerging area in Europe, TCM research requires collaboration and coordination of actions. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era, also known as GP-TCM, is the first ever EU-funded 7th Framework Programme (FP7) coordination action, aiming to inform the best practice and harmonise research on the safety and efficacy of TCM through interdisciplinary exchange of experience and expertise among clinicians and scientists. With its increasingly large pool of expertise across 19 countries including 13 EU member states, Australia, Canada, China, Norway, Thailand and the USA, the consortium provides forums and collaboration platforms on quality control, extraction technology, component analysis, toxicology, pharmacology and regulatory issues of Chinese herbal medicine (CHM), as well as on acupuncture studies, with a particular emphasis on the application of a functional genomics approach. The project officially started in May 2009 and by the time of its conclusion in April 2012 a Europe-based academic society dedicated to TCM research will be founded to carry on the mission of GP-TCM.
传统医学（TCM）在欧盟（EU）中被广泛应用，并引起了欧洲科学家的浓厚研究兴趣。作为欧洲的一个新兴领域，TCM 研究需要合作和协调行动。《后基因组时代传统医学研究的良好实践》（Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era，简称 GP-TCM）是首个由欧盟资助的第七框架计划（FP7）协调行动，旨在通过临床医生和科学家之间的跨学科经验和专业知识交流，告知 TCM 安全性和有效性研究的最佳实践，并协调研究。该联盟拥有来自 19 个国家的专业知识，包括 13 个欧盟成员国、澳大利亚、加拿大、中国、挪威、泰国和美国，提供了关于中药（CHM）的质量控制、提取技术、成分分析、毒理学、药理学和监管问题，以及针灸研究的论坛和合作平台，特别强调应用功能基因组学方法。该项目于 2009 年 5 月正式启动，到 2012 年 4 月项目结束时，将成立一个专门从事 TCM 研究的欧洲学术协会，以继续执行 GP-TCM 的使命。
